

To: David Lester[dlester@theranos.com]; Lipset, Crai [REDACTED]
Cc: Unnikrishnan, Roop [REDACTED] Seth Michelson[smichelson@theranos.com]
From: Elizabeth Holmes/[O=THERANOS ORGANIZATION/OU=FIRST ADMINISTRATIVE
GROUP/CN=RECIPIENTS/CN=EHOLMES]
Sent: Wed 8/26/2009 6:19:18 PM (UTC)
Subject: RE: momentum -- IL-6

David,
Thanks for this.
I will connect with Seth today.
Let's talk to Roopa about our goals this Friday and we'll circle back from there.
Elizabeth.

From: David Lester
Sent: Wednesday, August 26, 2009 5:56 AM
To: 'Lipset, Craig'
Cc: Unnikrishnan, Roopa; Seth Michelson; Elizabeth Holmes
Subject: RE: momentum -- IL-6

Hi Craig,
I have cc'ed Seth Michelson to follow up with you.
Seth, all yours.
Elizabeth, anything further?
Let me know how I can help.
Regards
David

From: Lipset, Craig [REDACTED]
Sent: Tuesday, August 25, 2009 6:41 AM
To: David Lester
Cc: Unnikrishnan, Roopa
Subject: momentum -- IL-6

David,

We are pursuing several potential engagement as a result of the recent meeting together. One particular opportunity has momentum, however, and so I would like to suggest some quick follow-up and engagement with the product team.

A team developing a MAb for IL-6 has modeling needs. Their first-in-human trial has just begun – there would not be any analytical needs for this program (although samples may become available). However this could provide a good timecycle to engage the team, develop a model, and identify analytical potential. As discussed in the meeting, this provides an opportunity for engagement around early development, in particular around inflammation.

Could you suggest a technical resource who can discuss IL-6 modeling capabilities with this team?

Best,
Craig

Craig Lipset
Pfizer, Inc.
685 Third Ave, NY, NY 10017
[REDACTED]
[REDACTED]